No
material or nonsubstantive change to a currently approved
collection
No
Emergency
10/28/2024
12/05/2024
Requested
Previously Approved
03/31/2025
03/31/2025
2,850
2,850
663
663
0
0
Beginning in late 2023, Oropouche
virus was identified as the cause of multiple outbreaks with over
10,000 cases from 6 countries reported in 2024 as of October 15.
With these outbreaks, the virus was reported to cause disease cases
in new non-endemic areas, result in the first reported deaths, be
associated with fetal demise and congenital anomalies, and be found
in the semen of an infected traveler. Although local transmission
of the virus has not been detected yet in the United States, the
vectors capable of transmitting the virus are present in many
states and at least 90 cases of U.S. travelers returning to the
United States while infected with the virus have been reported. All
of these findings and factors, raise concerns about the broader
threat this virus represents to the United States. There are
numerous gaps in our understanding of this emerging virus,
including the urgent need to evaluate the possibility of sexual
transmission to inform prevention recommendations, especially for
pregnant people and their partners, or those considering pregnancy.
This Non-Substantive Change Request is submitted to CDC is
requesting non-substantive changes to the Initial Clinical and
Social Survey, Contract Tracing Survey, and Sexual Contact
Interview forms. The purpose of this change is to address feedback
from state partners and streamline the data collection by providing
clarifying language regarding the timeframes of interest for both
individuals who consent to participate and staff conducting the
interviews. There is no change to the overall burden hours
previously approved for the 0920-1446 data collection.
This is an emergency
request for a new information collection for six months (180 days).
This information is essential to CDC’s mission to protect America
from health, safety, and security threats. The purpose of this
investigation is to better define the risk factors, clinical
course, viral shedding, and potential for sexual transmission among
patients with Oropouche virus disease. The findings of this
investigation will inform prevention guidance, improve clinical
recognition and diagnosis, ultimately aiding our ability to detect
and respond to Oropouche virus disease outbreaks. This information
collection request (ICR) needs to go forward as an Emergency to
avoid any delays in collecting essential actionable information in
this rapidly evolving situation. Beginning in late 2023, Oropouche
virus was identified as the cause of multiple outbreaks with over
10,000 cases from 6 countries reported in 2024 as of October 15.
With these outbreaks, the virus was reported to cause disease cases
in new non-endemic areas, result in the first reported deaths, be
associated with fetal demise and congenital anomalies, and be found
in the semen of an infected traveler. Although local transmission
of the virus has not been detected yet in the United States, the
vectors capable of transmitting the virus are present in many
states and at least 90 cases of U.S. travelers returning to the
United States while infected with the virus have been reported. All
of these findings and factors, raise concerns about the broader
threat this virus represents to the United States. There are
numerous gaps in our understanding of this emerging virus,
including the urgent need to evaluate the possibility of sexual
transmission to inform prevention recommendations, especially for
pregnant people and their partners, or those considering
pregnancy.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.